Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase.
E WeisshaarJacek Cezary SzepietowskiJ D BernhardH HaitF J LegatL NattkemperA ReichBirgit SadoghiT R SciasciaClaudia ZeidlerG YosipovitchPamela GuglielminiPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
In adult subjects with PN, oral treatment with NAL-ER 162 mg twice daily provided measurable anti-pruritic efficacy in subjects completing ≥10 weeks of treatment and was well tolerated (ClinicalTrials.gov: NCT02174419).